Cite
HARVARD Citation
Walker, L. et al. (2022). An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2. Clinical pharmacology & therapeutics. 111 (3), pp. 585-594. [Online].